William Tap, who is one of the lead international coordinating investigators and chair of the international steering committee for the phase III trial for synovial sarcoma patients.
Possible good news for the approximately 75-80% of synovial sarcoma patients whose tumors express the cancer antigen NY-ESO-1. In phase I testing, the new immunotherapy drug CMB305 was very effective against synovial sarcoma (median overall survival was not reached at the time of analysis). Additionally, CMB306 had few adverse effects with the most common being injection-site related. Additional trials are ongoing to see if CMB305 works against other cancers expressing NY-ESO-1.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518519/
Contributed by Marc Shinebarger
